Canada Pension Plan Investment Board Sells 54,100 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Canada Pension Plan Investment Board lessened its position in Omnicell, Inc. (NASDAQ:OMCL) by 94.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,400 shares of the company’s stock after selling 54,100 shares during the period. Canada Pension Plan Investment Board’s holdings in Omnicell were worth $151,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after purchasing an additional 699,925 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after buying an additional 377,883 shares during the period. Renaissance Technologies LLC increased its position in shares of Omnicell by 79.3% during the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company’s stock worth $20,316,000 after acquiring an additional 201,831 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Omnicell by 46.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company’s stock worth $19,130,000 after acquiring an additional 135,650 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Omnicell in the 4th quarter valued at $5,372,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

OMCL opened at $30.96 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The business has a fifty day simple moving average of $34.32 and a 200 day simple moving average of $40.85. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a market capitalization of $1.45 billion, a PE ratio of 114.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Benchmark reiterated a “buy” rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company decreased their price target on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Finally, StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Friday. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $50.67.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.